Related by context. All words. (Click for frequent words.) 64 immunosuppression 64 CMV disease 63 disease GVHD 63 lupus nephritis 63 GvHD 62 nephrotoxicity 62 acute GvHD 61 reperfusion injury 60 myeloma cells 60 VZV 60 immunosuppressive drugs 60 CMV reactivation 60 CMV infection 60 immunosuppressive therapies 60 basiliximab 59 chronic GVHD 59 mycophenolate mofetil 59 immunosuppressive agents 59 immune suppression 59 EGFR inhibitors 59 Graft versus 59 severe neutropenia 59 allogeneic stem cell 59 tyrosine kinase inhibitors 59 amphotericin B 58 leukemia ALL 58 ADPKD 58 idarubicin 58 allogeneic bone marrow 58 Lupus nephritis 58 acute GVHD 58 leukemia CLL 58 tumor recurrence 58 chlorambucil 58 hematopoietic stem cell 58 canakinumab 57 palifermin 57 imatinib 57 IFN alpha 57 Host Disease GvHD 57 sirolimus 57 bortezomib 57 hematologic disorders 57 hematopoietic cell 57 myelofibrosis 57 donor marrow 57 CLL cells 57 cisplatin chemotherapy 57 PTLD 57 visilizumab 57 azacitidine 57 SHPT 57 systemic lupus erythematosus SLE 56 allograft rejection 56 immune reconstitution 56 alkylating agent 56 allogeneic SCT 56 iron overload 56 bleomycin 56 Thrombocytopenia 56 transplantation HCT 56 cytotoxic chemotherapy 56 chemotherapeutic agent 56 corticosteroid therapy 56 transplanted islets 56 metastatic RCC 56 Host Disease 56 topotecan 56 immunosuppressants 56 Etanercept 56 HCV infection 56 myelosuppression 56 chemotherapeutic agents 56 delayed CINV 56 febrile neutropenia 56 DFMO 56 Immunosuppressive drugs 56 gastrointestinal stromal tumors GIST 56 hepatocellular carcinoma 56 HSCT 56 Disease GVHD 56 neutralizing antibody 56 infliximab 56 pancreatic adenocarcinoma 56 varicella zoster virus 56 VEGF inhibitors 55 EGFr 55 disease progression 55 sunitinib 55 colorectal liver metastases 55 Sym# 55 SSc 55 cyclosporine 55 myeloablative 55 tacrolimus 55 imatinib therapy 55 metastatic tumors 55 Doxil ® 55 invasive fungal infections 55 steroid refractory 55 Interferon alpha 55 chemotherapies 55 trans retinoic acid 55 Gleevec resistant 55 FVIII 55 doxorubicin 55 Myelodysplastic Syndrome 55 adalimumab 55 multiple myeloma 55 allogeneic hematopoietic stem cell 55 allogeneic transplantation 55 solid tumors 55 seropositive patients 55 sulfasalazine 55 tumor metastases 55 antibody mediated 55 nucleoside analogues 55 Imatinib 55 belatacept 55 allogeneic transplants 55 Th1 cells 55 FSGS 55 calcineurin inhibitors 55 toxicities 55 relapsing remitting 55 allogenic 55 HBeAg negative 55 adefovir 55 GISTs 55 ganciclovir 55 metastatic renal cell carcinoma 55 HbF 55 mucositis 55 TACE 55 relapsed ovarian cancer 55 Nilotinib 55 docetaxel chemotherapy 54 B lymphocytes 54 Bortezomib 54 octreotide LAR 54 peginterferon 54 WT1 54 Cyclosporine 54 hepatitis C virus 54 Candida infections 54 Hemophilia B 54 mutated KRAS gene 54 dexrazoxane 54 chemotherapy induced neutropenia 54 acute gastrointestinal Graft 54 glucocorticoid 54 hematopoietic cells 54 chemoresistance 54 acute Graft 54 immunosuppressed patients 54 interferon alfa 54 rituximab Rituxan 54 invasive aspergillosis 54 posaconazole 54 Gleevec imatinib mesylate 54 idraparinux 54 renal toxicity 54 GBM tumors 54 efalizumab 54 effector cells 54 graft dysfunction 54 basal cell nevus syndrome 54 Neutropenia 54 recurrent glioblastoma multiforme 54 glioblastoma 54 Telintra 54 vWF 54 CMV infections 54 Pegasys ® 54 metastatic disease 54 G CSF 54 Toxicities 54 cell lymphoma CTCL 54 daunorubicin 54 IFN beta 54 imatinib mesylate 54 raltegravir 54 hypersensitivity reaction 54 mRCC 54 hepatitis C genotype 54 Valcyte 54 GIST tumors 54 CIPN 54 erythropoiesis 54 candidemia 54 chronic lymphocytic leukemia CLL 54 Traficet EN 54 transplanted bone marrow 54 interferon alpha 54 thrombotic complications 54 dose cytarabine 54 anthracyclines 54 fluorouracil 54 hepatic toxicity 54 relapsed MM 54 Rituximab 54 Hydroxyurea 54 leukemia AML 54 Critical Limb Ischemia CLI 54 panobinostat 54 allogeneic 54 metastatic melanoma 54 S. aureus infections 54 superficial bladder cancer 54 recurrent glioma 54 complete remissions 54 hormone refractory 54 anakinra 54 bone metastasis 54 interferon beta 54 rapamycin 54 neutralizing antibodies 54 dacarbazine 54 relapsing multiple sclerosis 54 antitumor effect 54 liver metastases 54 CIMZIA ™ 54 immunosuppressive medication 54 idiopathic pulmonary fibrosis IPF 54 chronic granulomatous disease 54 malignancies 54 erlotinib Tarceva ® 54 basal cell carcinomas 54 pimecrolimus 54 Candida infection 54 cytomegalovirus 54 erythropoietic 53 anti angiogenic drugs 53 Dasatinib 53 metastatic lung cancer 53 EGFR antibodies 53 immunosuppressive medications 53 hypercalcemia 53 CIMZIA TM 53 immunosuppressant 53 esophagitis 53 invasive candidiasis 53 Navelbine 53 postherpetic neuralgia 53 Fludarabine 53 cytogenetic responses 53 calcineurin inhibitor 53 Helicobacter pylori H. pylori 53 imatinib resistance 53 bone marrow 53 C1 INH 53 gastrointestinal toxicity 53 suppressor cells 53 chronic hepatitis B. 53 TRIOLEX 53 Hurler syndrome 53 TKIs 53 CsA 53 cisplatin 53 ATIR 53 autoantibodies 53 alteplase 53 neuroendocrine tumors 53 pegfilgrastim 53 severe oral mucositis 53 HER2 positive breast cancer 53 ACZ# 53 post herpetic neuralgia 53 HuLuc# 53 refractory chronic myeloid 53 metastatic neuroendocrine tumors 53 fibrosis 53 rituximab 53 cutaneous squamous cell carcinoma 53 leukemic cells 53 decitabine 53 platelet reactivity 53 hematologic toxicity 53 imatinib Gleevec 53 anthracycline chemotherapy 53 Myelofibrosis 53 metastatic colon cancer 53 dasatinib 53 immunosuppressant drug 53 tumor cells 53 Zoledronic acid 53 L dopa 53 rilonacept 53 chemotherapeutic drug 53 severe sepsis 53 mismatched bone marrow 53 basal cell carcinoma BCC 53 intravenous cyclophosphamide 53 sCD# 53 ISTODAX 53 hypereosinophilic syndrome 53 biologic therapy 53 natalizumab 53 octreotide 53 ceftriaxone 53 lymphocytes 53 engraftment 53 vinorelbine 53 follicular lymphoma 53 LHRH agonists 53 etanercept 53 Adalimumab 53 immuno suppressive 53 androgen receptor AR 53 antifungal therapy 53 AA amyloidosis 53 CMV seropositive 53 rhIL 7 53 refractory gout 53 metastatic malignant melanoma 53 deacetylase inhibitors 53 nonalcoholic steatohepatitis NASH 53 vWD 53 thrombocytosis 53 beta thalassemia 53 MALT lymphoma 53 PCa 53 tigecycline 53 immunosuppressive 53 zoledronic acid 53 TRAIL induced apoptosis 53 Noxafil 53 Bcl xL 53 inherited retinal degeneration 53 imipenem 53 sepsis 53 pegylated liposomal doxorubicin 53 T#I mutant 53 TNF α 53 epithelial tumors 53 interferon therapy 53 recurrent genital herpes 53 liver scarring 53 azathioprine 53 cidofovir 53 mitomycin C 53 virologic failure 53 hemorrhagic complications 53 chronic HCV 53 granulocytes 53 aprepitant 53 interferons 53 malignant pleural mesothelioma 53 adriamycin 53 OHR/AVR# 53 relapsing MS 53 KRAS mutant tumors 53 relapsed multiple myeloma 53 cinacalcet 53 cabazitaxel 53 medulloblastomas 53 molecularly targeted 52 Epratuzumab 52 standard chemotherapy regimens 52 hematological malignancy 52 lymphoid organs 52 Chronic Myeloid Leukemia CML 52 HBeAg seroconversion 52 atherosclerotic lesions 52 Hepatitis C virus 52 Idiopathic Thrombocytopenic Purpura ITP 52 anemias 52 lichen planus 52 Xanafide 52 cetuximab 52 B7 H3 52 erlotinib Tarceva 52 transplanted kidneys 52 insulin sensitizers 52 medulloblastoma 52 familial amyloidotic polyneuropathy FAP 52 posttransplant 52 renal allograft 52 disease GvHD 52 IFN gamma 52 refractory ovarian cancer 52 NNRTIs 52 uric acid lowering 52 P. falciparum parasites 52 Cutaneous T 52 recombinant erythropoietin 52 hyperkalemia 52 Neulasta ® 52 chronic myeloid leukemia CML 52 imatinib resistant 52 Tavocept 52 sarcomatoid 52 uPA 52 Treg cells 52 haematopoietic 52 transgene expression 52 systemic scleroderma 52 immune suppressants 52 eribulin 52 immunosuppressive regimens 52 inflammatory acne 52 metastatic malignant 52 moxifloxacin 52 seminoma 52 EBV infection 52 platelet deficiency 52 fibrinolytic 52 mononuclear cells 52 lymphoma CTCL 52 BRAF mutation 52 NAbs 52 hydroxyurea 52 synthetic retinoid 52 hepatitis C infection 52 allogeneic HSCT 52 immuno suppressive drugs 52 JAK3 52 receiving VICTRELIS 52 pyrazinamide 52 pulmonary hypertension PH 52 Tacrolimus 52 bone marrow stem cells 52 organ rejection 52 sorafenib Nexavar 52 Trastuzumab 52 milatuzumab 52 cardiac toxicity 52 varices 52 acute leukemias 52 BRAF mutations 52 CD8 responses 52 pancreatic islet 52 diabetic nephropathy 52 calcitriol 52 HBeAg negative patients 52 antiviral therapy 52 leukemic 52 bryostatin 52 deferiprone 52 grade cervical intraepithelial 52 gastrointestinal stromal tumor 52 azacytidine 52 virologic response 52 RSV infection 52 indolent NHL 52 tocilizumab 52 adult chronic ITP 52 cell lymphomas 52 TORISEL 52 nifurtimox 52 Fibrosis 52 pegylated interferon alfa 52 tumors 52 immunosuppressive regimen 52 melanoma tumors 52 von Willebrand factor 52 mitoxantrone 52 cytotoxin 52 sarcomas 52 viral suppression 52 metastatic cancer 52 type 1diabetes 52 post surgical adhesions 52 MMP inhibitors 52 Chronic lymphocytic leukemia 52 dyskeratosis congenita 52 chronic ITP patients 52 amoxicillin clavulanate 52 Cyclophosphamide 52 bendamustine 52 dasatinib Sprycel ® 52 imetelstat 52 organ transplant rejection 52 investigational monoclonal antibody 52 EGF receptor 52 pazopanib 52 Amigal 52 denileukin diftitox 52 Lymphomas 52 fulvestrant 52 olmesartan 52 carcinoid cancer 52 intravesical instillation 52 VAPRISOL 52 Everolimus 52 proteasome inhibitor 52 angiogenesis inhibitor 52 thrombocytopenia 52 Hepatitis C virus HCV 52 diuretic hydrochlorothiazide 52 somatostatin analogs 52 liver fibrosis 52 docetaxel Taxotere ® 52 gastrointestinal stromal tumor GIST 52 immunomodulator 52 Neovascular Age Related Macular 52 trastuzumab 52 myelofibrosis polycythemia vera 52 MYLOTARG 52 PRT# 52 systemic lupus erythematosus 52 Cisplatin 52 systemic immunosuppressive 52 Prochymal 52 anterior uveitis 52 bone marrow suppression 52 thalidomide Thalomid 52 immunosuppressive therapy 52 TGF beta signaling 52 pancreatic NET 52 autologous transplants 52 Gleevec imatinib 52 alefacept 52 anticancer therapy 52 IL 1ß 52 myasthenia gravis MG 52 grade glioma 52 stage IIIB 52 Myelodysplastic Syndrome MDS 52 ischemia reperfusion injury 52 pancreatic islet cells 52 chronic HBV infection 52 tipranavir 52 alpha interferons 52 metastatic GIST 52 stem cell transplantation 52 rFVIIa 52 antibody fragment 52 urothelial bladder cancer 52 mucosal immunity 52 K ras mutations 52 ATTR 52 neuroblastoma tumors 52 metastases 52 velafermin 52 administered subcutaneously 52 tumor regrowth 52 effector T 52 lamivudine 52 Elotuzumab 52 DHFR 51 bortezomib Velcade 51 IgG antibodies 51 TKI therapy 51 Cystinosis 51 Decitabine 51 docetaxel Taxotere 51 malignancy 51 carcinoid 51 etoposide 51 mycophenolate mofetil MMF 51 actinic keratoses 51 urothelial cancer 51 glioma cells 51 TTR gene 51 cyclosporin 51 Pemetrexed 51 GRNOPC1 cells 51 EGFR tyrosine kinase inhibitors 51 chemotherapeutic 51 TNF antagonist 51 IgE antibodies 51 HCV infected 51 recurrent GBM 51 flavopiridol 51 androgen deprivation 51 Kaposi sarcoma 51 differentiated thyroid 51 linezolid 51 Cremophor 51 immune responses 51 Cholangiocarcinoma 51 filgrastim 51 TNFa 51 oblimersen 51 plasma kallikrein 51 Acute GVHD 51 lymphopenia 51 abiraterone 51 Tumor Necrosis Factor 51 prostate cancer mCRPC 51 hedgehog pathway 51 immunosuppressed 51 MELD scores 51 chronic HCV infection 51 cisplatin resistant 51 Pegylated Interferon 51 hepatotoxicity 51 EGFRIs 51 NF kappaB activation 51 cranial irradiation 51 colorectal tumors 51 peptide antigens 51 HuMax CD4 51 SCIg 51 EGFR mutation 51 myelodysplastic syndrome MDS 51 effector function 51 EXJADE 51 Durezol 51 Velcade bortezomib 51 vancomycin 51 N acetylcysteine 51 myelodysplastic syndromes MDS 51 purpura 51 imatinib Gleevec ® 51 bezafibrate 51 thrombocytopenia neutropenia 51 pyrimethamine 51 Bcr Abl mutations 51 HBeAg positive 51 acne lesions 51 nasopharyngeal carcinoma 51 Vidofludimus 51 reinfection 51 bone marrow transplantation 51 T#I [002] 51 hyperphosphatemia 51 Cytoxan 51 refractory CML 51 Symadex 51 CTAP# Capsules 51 DAPT 51 APOL1 51 chemotherapeutic regimens 51 Calcineurin inhibitors 51 gemifloxacin 51 infusion reactions 51 secondary hyperparathyroidism 51 virological failure 51 systemic absorption 51 renal transplantation 51 tyrosine kinase inhibitor 51 atacicept 51 gastrointestinal stromal tumors 51 Laquinimod 51 lupus 51 immune suppressing 51 tyrosine kinase inhibitors TKIs 51 orBec 51 ribavirin RBV 51 bevacizumab Avastin 51 Immunosuppression 51 pneumocystis 51 bevacizumab Avastin ® 51 membranous nephropathy 51 immune mediated 51 YONDELIS 51 retinal vein occlusion 51 CD8 T cells 51 fluvastatin 51 APTIVUS r 51 elotuzumab 51 ifosfamide 51 parasitemia 51 neutrophil counts 51 efavirenz Sustiva 51 teriflunomide 51 Paraplatin ® 51 riociguat 51 nephrotic syndrome 51 heavily pretreated patients 51 opportunistic infections 51 Epivir 51 P. aeruginosa 51 PROCHYMAL 51 bronchogenic carcinoma 51 relapsed SCLC 51 immunosuppressant drugs 51 doxorubicin Adriamycin 51 metastatic cancers 51 herpes zoster virus 51 herpes zoster shingles 51 isoproterenol 51 TMP SMX 51 breast cancer metastasis 51 IgG1 antibody 51 depression TRD 51 prostate cancer CRPC 51 Treg cell 51 latent infection 51 angioedema 51 Akt activation 51 ADHF 51 allogeneic hematopoietic cell 51 pleural mesothelioma 51 varicella zoster virus VZV 51 azoles 51 gouty arthritis 51 CD8 + T 51 CLL 51 cytotoxicity 51 mycosis fungoides 51 exacerbations 51 colorectal carcinoma 51 IFN α 51 ara C 51 metastatic lesions 51 aortic dissections 51 IL 1beta 51 epirubicin 51 interferon IFN 51 myeloproliferative disorder 51 adrenal suppression 51 thrombotic events 51 lung fibrosis 51 FOLFIRI alone 51 locoregional 51 neutropenia 51 unresectable tumors 51 Follicular lymphoma 51 vandetanib 51 tolvaptan 51 serum HBV DNA 51 anti CD3 antibody 51 Acute myeloid leukemia 51 solar keratoses 51 lactic acidosis 51 acute promyelocytic leukemia 51 immune modulator 51 herpes infections 51 immunopathology 51 myopathy rhabdomyolysis 51 standard chemotherapy regimen 51 gemcitabine 51 chloride secretion 51 chemosensitivity 51 deferoxamine 51 H. pylori infection 51 leukaemic stem cells 51 oral JAK1 51 immunomodulators 51 chronic ITP 51 T2DM 51 latent tuberculosis infection 51 invasive fungal infection 51 mesenchymal cells 51 cholangiocarcinoma 51 esophageal candidiasis 51 myeloid 51 PARP inhibitors 51 diabetic kidney 51 lymphoproliferative disorder 51 Ilaris 51 leukopenia 51 Hypotension 51 hormone deprivation 51 lumiliximab 51 cytomegalovirus CMV 51 cell acute lymphoblastic 51 islet cells 51 colorectal cancer liver metastases 51 immune suppressive cells 51 purpura ITP 51 renal cell carcinoma 51 hepatorenal syndrome 51 paroxysmal AF 51 rifamycins 51 bone metastases 51 Th2 51 mucosal healing 51 Unstable angina 51 gout flare 51 hepatocellular carcinoma HCC 51 antiangiogenic 51 interferon 51 intermittent claudication 51 Kepivance 51 ximelagatran 51 humanized antibody 51 Islet transplantation 51 taxol 51 polycythemia vera 51 pyridostigmine 51 preoperative chemotherapy 51 Hodgkin lymphoma NHL 51 pheochromocytoma 51 Th2 cells 51 uveitis 51 MyVax R 51 acromegaly 51 acute myelogenous leukemia AML 51 thromboembolic events 51 monoclonal antibody therapies 51 HBeAg positive patients 51 platelet transfusions 51 NRTIs 51 leukemia CML 51 temsirolimus 51 HIV Lalezari 51 Abatacept 51 gefitinib 51 fibrotic disease 51 disease GI GVHD 51 cetuximab Erbitux ® 50 Chronic Myeloid Leukemia 50 primary biliary cirrhosis 50 neutrophil 50 Carcinoid tumors 50 L asparaginase 50 neutropenic 50 GPIIb IIIa 50 heterozygous FH 50 autologous SCT 50 cutaneous melanoma 50 Omacetaxine mepesuccinate 50 elacytarabine 50 nonsense mutations 50 antihypertensive therapy 50 autoimmune reactions 50 Erlotinib 50 cardiolipin 50 antibodies 50 BH4 50 intravenous bisphosphonates 50 PEGPH# 50 non metastatic osteosarcoma 50 PAOD 50 neoadjuvant chemotherapy 50 AGILECT R 50 antiplatelet therapy 50 angiotensin converting enzyme inhibitors 50 acute lymphoblastic leukemia 50 proteasome inhibitors 50 EpCAM 50 haematological toxicity 50 Irinotecan 50 tumor vasculature 50 GI GVHD 50 EGFR mutations 50 intensive statin therapy 50 maribavir 50 ancrod 50 thrombocytopenic 50 H pylori 50 primidone 50 autologous stem cell 50 Follicular Lymphoma 50 severe rotavirus gastroenteritis 50 immuno suppression 50 hemolytic anemia 50 nucleoside analog 50 sodium glucose cotransporter 50 lipoatrophy 50 antithrombotic therapy 50 selegiline 50 erlotinib 50 5FU 50 FOLFOX4 50 systemic corticosteroid 50 Doxorubicin 50 deletion 5q 50 lapatinib Tykerb 50 venous blood clots 50 imiquimod cream 50 XmAb# 50 pegylated interferons 50 lesinurad 50 distant metastases 50 immunocompetent patients 50 TNF alpha 50 neutrophils 50 immunomodulatory therapies 50 Cryptococcus neoformans 50 chronic myelogenous leukemia CML 50 S. aureus isolates 50 lymphoid 50 Adefovir 50 renal tumors 50 cytotoxic effects 50 colon carcinoma 50 Vascugel 50 IFNs 50 cyclophosphamide methotrexate 50 psoriasis 50 neoadjuvant therapy 50 osteoclast activity 50 tumoral 50 chronic plaque psoriasis 50 darapladib 50 FASLODEX 50 fondaparinux 50 taxane chemotherapy 50 underlying vasculopathy 50 transaminase elevations 50 acute promyelocytic leukemia APL 50 mitochondrial toxicity 50 Graft Versus Host 50 GRK2 50 atopic disease 50 recurrent glioblastoma 50 refractory angina 50 familial ALS 50 evaluating tivozanib 50 HBV vaccine 50 symptomatic hypotension 50 virological response 50 Torisel 50 pegylated interferon ribavirin 50 tobramycin 50 Epstein Barr virus EBV 50 bexarotene 50 rFIXFc 50 Bcr Abl 50 systemic toxicity 50 oral prodrug 50 NKT cells 50 LHRH antagonists 50 carcinoid tumors 50 IRX 2 50 FVIIa 50 urinary tract infections UTIs 50 atypical hemolytic uremic syndrome 50 dasatinib Sprycel 50 rituximab Rituxan ® 50 gliomas 50 IGFBP 3 50 immunosuppressant medications 50 oral vancomycin 50 BRAF V#E 50 CDDO Im 50 Chronic Lymphocytic Leukemia CLL 50 HPV infections 50 NF kB pathway 50 Natalizumab 50 liposomal doxorubicin 50 torsade de pointes 50 5 Fluorouracil 50 CANCIDAS 50 Cell Lymphoma CTCL 50 HAART regimen 50 medullary thyroid cancer 50 huC# DM4 50 acid secretion 50 sorafenib 50 ALN TTR# 50 mCRC patients 50 HBV replication 50 cutaneous lesions 50 EGFR receptor 50 Romiplostim 50 metastatic prostate cancer 50 intracranial hemorrhage ICH 50 PDGF receptor 50 fluid overload 50 ovarian tumors 50 cytoreduction 50 Acute Myelogenous Leukemia AML 50 HAART regimens 50 recurrent venous thromboembolism 50 anthracycline taxane 50 talabostat 50 Desferal 50 Fludara 50 autoreactive T cells 50 ribavirin therapy 50 pneumococcal pneumonia 50 activin 50 autologous bone marrow 50 corticosteroid dexamethasone 50 atopic eczema 50 associated lymphoid tissue 50 heavily pretreated 50 antiangiogenic therapy 50 sorafenib Nexavar ® 50 IGIV 50 essential thrombocythemia 50 Glioblastoma multiforme GBM 50 NOMID 50 Aliskiren 50 fallopian tube carcinoma 50 tumor xenograft models 50 cardiotoxicity 50 antibody mediated rejection 50 voriconazole 50 G#DT 50 recurrent ovarian cancer 50 levodopa 50 nephropathy 50 panitumumab Vectibix 50 registrational clinical 50 BCR ABL mutations 50 idiopathic thrombocytopenic purpura ITP 50 anticancer therapies 50 variceal bleeding 50 VIDAZA 50 refractory NSCLC 50 myelodysplastic syndrome 50 MGUS 50 intradermal injection 50 Alemtuzumab 50 durable remissions 50 mTOR inhibitors 50 BCL#A 50 experimental autoimmune encephalomyelitis 50 antithymocyte globulin 50 variceal hemorrhage 50 beclomethasone dipropionate 50 Naive Patients